THERAPY DOSSIER · th-c7508f0a0b7f

BML-111

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS · Chemical/toxin · Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 4

4 studies reported at therapy level; 4 evidence entries itemised.

PMID 33383086 ↗2020Reported benefit

The LipoxinA4 receptor agonist BML-111 ameliorates intestinal disruption following acute pancreatitis through the Nrf2-regulated antioxidant pathway.

MouseChemical/toxin

Model: Acute pancreatitis with associated intestinal epithelial disruption

BML-111 increased E-cadherin, reduced apoptosis and reactive oxygen species and lessened pancreatic and intestinal injury, and these protective effects were abolished in Nrf2 deficient cells and Nrf2 knockout mice.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

PMID 30784911 ↗2019Reported benefit

Effects of the ALX/FPR2 receptors of lipoxin A on lung injury induced by fat embolism syndrome in rats.

RatOtherSprague-DawleyMale

Model: Fat embolism syndrome-induced acute lung injury

Fat embolism increased lung injury score, wet-to-dry ratio, BALF protein, leukocytes, neutrophils, myeloperoxidase, TNF-alpha and IL-1beta, alongside raised lipoxin A4 and upregulated ALX/FPR2. BML-111 lowered the inflammatory response, and this benefit was attenuated by the ALX/FPR2 antagonist BOC…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

PMID 30412790 ↗2018Reported benefit

BML-111, a lipoxin receptor agonist, protects against acute injury via regulating the renin angiotensin-aldosterone system.

RatEndotoxin/LPSSprague-Dawley

Model: Lipopolysaccharide-induced acute lung injury and lipopolysaccharide plus D-galactosamine induced acute liver injury

BML-111 protected against lipopolysaccharide-induced acute lung injury and lipopolysaccharide plus D-galactosamine induced acute liver injury, repressing angiotensin converting enzyme activity and increasing ACE2 activity, with all effects reversed by the lipoxin receptor inhibitor BOC-2.

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

PMID 23802775 ↗2013Reported benefit

BML-111, a lipoxin receptor agonist, ameliorates 'two-hit'-induced acute pancreatitis-associated lung injury in mice by the upregulation of heme oxygenase-1.

MouseEndotoxin/LPSBALB/cn = 128 mice randomly allocated to four groupsPretreatment before induction of pancreatitis

Model: Acute pancreatitis-associated lung injury produced by seven hourly intraperitoneal injections of cerulein followed immediately by a single dose of Escherichia coli lipopolysaccharide (two-hit model)

Pretreatment with BML-111 lowered serum amylase, TNF-alpha and IL-1 beta, raised IL-10, reduced lung wet to dry weight ratio and pancreatic and pulmonary histological injury scores, and increased pulmonary heme oxygenase-1 expression compared with the untreated injury group.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…